Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26924205 | 0.94 | USP30 (0.41) | USP30PDK2UCHL1FFAR1DGAT1 | |
| SCHEMBL26924398 | 0.91 | USP30 (0.40) | USP30PDK2UCHL1FFAR1DGAT1 | |
| SCHEMBL26924481 | 0.90 | USP30 (0.40) | USP30PDK2UCHL1FFAR1DGAT1 | |
| SCHEMBL26927322 | 0.79 | USP30 (0.44) | USP30UCHL1FFAR1AAK1 | |
| SCHEMBL24192139 | 0.78 | USP30 (0.38) | USP30UCHL1FFAR1 | |
| SCHEMBL26926712 | 0.77 | SCN9A (0.39) | USP30PDK2UCHL1DGAT1AAK1 | |
| SCHEMBL26927086 | 0.77 | DUT (0.33) | UCHL1FFAR1 | |
| SCHEMBL26926611 | 0.77 | USP30 (0.39) | USP30PDK2FFAR1DGAT1AAK1 | |
| SCHEMBL24192519 | 0.76 | USP30 (0.36) | USP30PDK2AAK1 | |
| SCHEMBL26927122 | 0.75 | USP30 (0.37) | USP30PDK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4536225-A1 | INDAZOLE MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023240140-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240140-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | USP30 4589/4885PDK2 3630/4885UCHL1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.